Cycle Pharmaceuticals to Acquire Applied Therapeutics for $0.088 Per Share Plus CVR

Reuters12-12

Cycle Pharmaceuticals to Acquire <a href="https://laohu8.com/S/AMAT">Applied</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> for $0.088 Per Share Plus CVR

Cycle Group Holdings Limited has reached a definitive agreement to acquire Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treatments for rare diseases. Under the agreement, Cycle will launch a tender offer to purchase all outstanding shares of Applied Therapeutics for $0.088 per share in cash at closing, along with one non-transferrable contingent value right $(CVR)$ per share, which may provide additional payments based on future milestones. The boards of both companies have approved the transaction, which is expected to close in the first quarter of 2026, subject to customary closing conditions. Applied Therapeutics' lead drug candidate, govorestat, is being developed for several rare central nervous system metabolic diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601123) on December 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590254407?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590254407","market":"us","top_or_hot":-1,"title":"Cycle Pharmaceuticals to Acquire Applied Therapeutics for $0.088 Per Share Plus CVR","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cycle Pharmaceuticals to Acquire <a href=\"https://laohu8.com/S/AMAT\">Applied</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for $0.088 Per Share Plus CVR\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cycle Group Holdings Limited has reached a definitive agreement to acquire Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treatments for rare diseases. Under the agreement, Cycle will launch a tender offer to purchase all outstanding shares of Applied Therapeutics for $0.088 per share in cash at closing, along with one non-transferrable contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> per share, which may provide additional payments based on future milestones. The boards of both companies have approved the transaction, which is expected to close in the first quarter of 2026, subject to customary closing conditions. Applied Therapeutics' lead drug candidate, govorestat, is being developed for several rare central nervous system metabolic diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/APLT\">Applied Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601123) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cycle Pharmaceuticals to Acquire Applied Therapeutics for $0.088 Per Share Plus CVR</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCycle Pharmaceuticals to Acquire Applied Therapeutics for $0.088 Per Share Plus CVR\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 06:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cycle Pharmaceuticals to Acquire <a href=\"https://laohu8.com/S/AMAT\">Applied</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for $0.088 Per Share Plus CVR\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cycle Group Holdings Limited has reached a definitive agreement to acquire Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treatments for rare diseases. Under the agreement, Cycle will launch a tender offer to purchase all outstanding shares of Applied Therapeutics for $0.088 per share in cash at closing, along with one non-transferrable contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> per share, which may provide additional payments based on future milestones. The boards of both companies have approved the transaction, which is expected to close in the first quarter of 2026, subject to customary closing conditions. Applied Therapeutics' lead drug candidate, govorestat, is being developed for several rare central nervous system metabolic diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/APLT\">Applied Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601123) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL6Xg7r:1","article_id":"2590254407","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590254407","pubTimestamp":1765491915,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cycle Group Holdings Limited has reached a definitive agreement to acquire Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treatments for rare diseases. Under the agreement, Cycle will launch a tender offer to purchase all outstanding shares of Applied Therapeutics for $0.088 per share in cash at closing, along with one non-transferrable contingent value right  per share, which may provide additional payments based on future milestones. The boards of both companies have approved the transaction, which is expected to close in the first quarter of 2026, subject to customary closing conditions. Applied Therapeutics' lead drug candidate, govorestat, is being developed for several rare central nervous system metabolic diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","APLT":"Applied Therapeutics Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4588":"碎股","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Cycle Pharmaceuticals将以每股0.088美元加CVR收购Applied Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLT":0.9,"NDAQ":0.9},"content_text":"Cycle Pharmaceuticals to Acquire Applied Therapeutics for $0.088 Per Share Plus CVR\n    \n\n        Cycle Group Holdings Limited has reached a definitive agreement to acquire Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treatments for rare diseases. Under the agreement, Cycle will launch a tender offer to purchase all outstanding shares of Applied Therapeutics for $0.088 per share in cash at closing, along with one non-transferrable contingent value right $(CVR)$ per share, which may provide additional payments based on future milestones. The boards of both companies have approved the transaction, which is expected to close in the first quarter of 2026, subject to customary closing conditions. Applied Therapeutics' lead drug candidate, govorestat, is being developed for several rare central nervous system metabolic diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601123) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590254407","isCrawlerRequest":true}